Plasma CCL5 promotes EMT-medicated epirubicin-resistance in locally advanced breast cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Plasma CCL5 promotes EMT-medicated epirubicin-resistance in locally advanced breast cancer
Authors
Keywords
-
Journal
Cancer Biomarkers
Volume 22, Issue 3, Pages 405-415
Publisher
IOS Press
Online
2018-05-11
DOI
10.3233/cbm-170986
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Interaction Between Ezrin and Cortactin in Promoting Epithelial to Mesenchymal Transition in Breast Cancer Cells
- (2017) Jing He et al. MEDICAL SCIENCE MONITOR
- Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I–III Triple-Negative Breast Cancer
- (2015) Carolyn Hall et al. ANNALS OF SURGICAL ONCOLOGY
- Breast cancer and immunology: biomarker and therapeutic developments
- (2015) Cesar A Santa-Maria et al. Expert Review of Anticancer Therapy
- Recent Advances in Discovering the Role of CCL5 in Metastatic Breast Cancer
- (2015) Ayesha Khalid et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- The Inflammatory Chemokine CCL5 and Cancer Progression
- (2014) Donatella Aldinucci et al. MEDIATORS OF INFLAMMATION
- The role of anthracyclines in the treatment of early breast cancer
- (2014) John Greene et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- CCL5 as a potential immunotherapeutic target in triple-negative breast cancer
- (2013) Dandan Lv et al. Cellular & Molecular Immunology
- CCR5 Antagonist Blocks Metastasis of Basal Breast Cancer Cells
- (2012) M. Velasco-Velazquez et al. CANCER RESEARCH
- Involvement of the Src-cortactin pathway in migration induced by IGF-1 and EGF in human breast cancer cells
- (2012) SILVIA MEZI et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- STAT3-RANTES Autocrine Signaling Is Essential for Tamoxifen Resistance in Human Breast Cancer Cells
- (2012) E. H. Yi et al. MOLECULAR CANCER RESEARCH
- Inflammatory mediators in breast cancer: Coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition
- (2011) Gali Soria et al. BMC CANCER
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Cortactin Controls Cell Motility and Lamellipodial Dynamics by Regulating ECM Secretion
- (2011) Bong Hwan Sung et al. CURRENT BIOLOGY
- The 2011 EBCTCG polychemotherapy overview
- (2011) Carlo Palmieri et al. LANCET
- ER, PgR, HER-2, Ki-67, topoisomerase IIα, and nm23-H1 proteins expression as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer
- (2010) Xi-ru Li et al. MEDICAL ONCOLOGY
- Twist1-Mediated Adriamycin-Induced Epithelial-Mesenchymal Transition Relates to Multidrug Resistance and Invasive Potential in Breast Cancer Cells
- (2009) Q.-Q. Li et al. CLINICAL CANCER RESEARCH
- Induction of Cancer Metastasis by Cyclophosphamide Pretreatment of Host Mice: An Opposite Effect of Chemotherapy
- (2008) K. Yamauchi et al. CANCER RESEARCH
- Combined Use of Clinical and Pathologic Staging Variables to Define Outcomes for Breast Cancer Patients Treated With Neoadjuvant Therapy
- (2007) Jacqueline S. Jeruss et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started